Atrial fibrillation in dialysis patients

Nephrology Dialysis Transplantation

Volumn 15, Issue 6, 2000, Pages 765-768

  Zebe, Horst ^a  

^a Fachklinik der Fürstenhof   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DIGITALIS; DISOPYRAMIDE; ENCAINIDE; ESMOLOL; FLECAINIDE; METOPROLOL; MORACIZINE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; VERAPAMIL;

BRADYCARDIA; CATARACT; CONTROLLED STUDY; ELECTROSTIMULATION THERAPY; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEMODIALYSIS PATIENT; HUMAN; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOTHYROIDISM; NOTE; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES;

EID: 0034109243     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.6.765     Document Type: Note

References (29)

1. Pozzoli M, Cioffi G, Travosi E. et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32: 197-204
2. Harnett JD, Foley RN, Kent GM, Barre PK, Murray DC, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890
3. Kimura K, Tabei K, Asano Y, Hosodu S. Cardiac arrhythmics in hemodialysis patients. A study of incidence and contributary factors. Nephron 1989; 53: 201-207
4. Sanfilippo AJ, Abascal VM, Sheehan M et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990; 82: 792-797
5. Benjamin EF, Wolf PA, D'agostin RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 1998; 98: 946-952
6. Wijffels MCEF, Kirchhof CJHJ, Darland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. Circulation 1995; 92: 1-15
7. Tröster S, Schuster HP, Bochmann KF. Vorhofflimmern bei Patienten einer med. Klinik - ein Marker für Multimorbidität und ungünstige Prognose. Med Klinik 1991; 86: 338-343
8. Flaherty JF, Pharm D, Wong B et al. Pharmacokinetics of esmolol and ASL - 8123 in renal failure. Clin Pharmacol Ther 1989; 45: 321-327
9. Brodsky MA, Chung JG, Podrid PJ, Douban S, Allan BJ, Cygan R. Regional attitudes of generalists specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996; 156: 2553-2562
10. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardmann JG, Gilmann AG, Limbird LE, eds, Goodmann A Gilman's The Pharmacologial Basis of Therapeutics. McGraw-Hill, NY, 1996; 1707-1792
11. Ueda CT. Quinidine. In: Evans WE, Schentag JJ, Jasko WJ, eds, Applied Pharmacokinetics: Principles of Therapeutics Drug Monitoring. Applied Therapeutics Vancouver, Wash, 1992: 23-1 23-22
12. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994; 331: 785-791
13. Roden DM, Woosley RL, Primen PK. Incidence and clinical features of the quinidine-associated long QT-syndrome: implications for patients care. Am Heart J 1986; 111: 1088-1093
14. Coplen SE, Autmann EM, Berlin JA, Hewitt P, Chalmas TC. Efficacy and safety of quinidinc therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106-1116
15. Innes GD, Vertesi L, Dillon EC, Metcalfe C. Effectiveness of verapamil quinidinc versus digoxin quinidine in the emergency department treatment of paroxysmal atrial fibrillation. Ann Emerg Med 1997; 29: 126-234
16. Trappe HJ, Pfitzner P. Konversionsrate und Rezidivprophylaxe bei paroxysmalem und anhaltendem Vorhofflimmern oder Vorhofflattern mit Verapamil/Chinidin. Med Klinik 1996; 91: 617-625
17. Patten M, Koch H-P, Sonntag F, Lüderitz B, Meinertz Th. Die medikamentöse Anfallsprophylaxe bei symptomatischem Vorhofflimmern/-flattern. Ziele und Design der SOPA-Studie. Z Kardiol 1999; 88: 185-194
18. Naitoh M, Tuminaga T, Suzuki H, Saruta T, Deguchi N. Antiarrhythmic agent caused marked hypoglycemia in a patient receiving hemodialysis: relation with disopyramide and verapamil. Nippon Naibunpi Gakkai Zasshi 1988; 64: 1115-1123
19. Capucci A, Villani GQ, Piepoli MF, Aschieri D. The role of antiarrhythmic drugs in terminating atrial fibrillation. Curr Opin Cardiol 1999; 15: 4-8
20. Lüderitz B. (Hrsg.) Therapie der Herzrhythmusstörungen. Leitfaden für Klinik und Praxis. Springer-Verlag, Berlin. 5 Auflage, 1998
21. Palatia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63: 925-929
22. Wiest D. Esmolol: A review of its therapeutic efficiency and pharmacokinetic characteristics. Clin Pharmacokinet 1995; 28: 140-202
23. Bährle S, Schöls W. Torsade de pointes in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 944-946
24. Huyn-Do K, Wahl C, Sulzer M, Bühler H, Keusch G. Torsade de pointes during low-dosage sotalol therapy in haemodialysis patients. Nephrol Dial Transplant 1995; 11: 1153-1154
25. Gosselink ATM, Crigus HJGM, Gelder IC van, Hillige H, Wiestfeld ACP, Lie KI. Low dose amiodarone for maintenance of sinus rhythm after cardiovcrsion of atrial fibrillation or flutter. J Am Med Assoc 1992; 267: 3289-3293
26. Middlekauf HR, Wiener I, Stevenson WG. Low dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72: 75 F-81 F
27. Waxmann HG, Myerburg RJ, Appel R. Verapamil for control of paroxysmal supraventricular tachycardia and atrial fibrillation or flutter. Ann Intern Med 1981; 94: 1-6
28. Kates RE, Keefc D, Schwartz JB. Disposition kinetics of verapamil in patients with chronic atrial fibrillation. Clin Pharmacol Ther 1981; 30: 44-50
29. Botto GL, Bonini W, Broffoni T et al. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. PACE Pacing Clin Electrophysiol 1995; 21: 2114-2117